FOR TRANSLATIONAL RESEARCH IN NUCLEAR MEDICINE
Arronax Nantes brings together all stakeholders in Nantes working on research and development in nuclear medicine.
This more particularly include the GIP ARRONAX, the laboratories Ceisam, CEMA-Oniris, CRCI2NA, LS2N, Subatech, the CRIP-Oniris core facility and the Nuclear Medicine departments of the University Hospital of Nantes and the ICO.
Arronax Nantes is a stakeholder in the I-SITE NExT, in close collaboration with the LabEx IRON and the SIRIC ILIAD.
our publications
Validation of the ΔSUVmax for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical study. Itti E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, Kraeber-Bodéré F, Meignan M, Gat E, Le Gouill S, Casasnovas RO, Bodet-Milin C. J Nucl Med. 2023, 64: 1706-1711. https://doi.org/10.2967/jnumed.123.265871
Multiple myeloma mimicking metastatic skull base paraganglioma in [68 Ga]Ga-DOTATOC-PET/CT and 2-[18F]FDG-PET/CT imaging. Jamet B, Bodet-Milin C, Moreau P, Touzeau C, Kraeber-Bodéré F. Eur J Nucl Med Mol Imaging. 2023, 3792-3793. https://doi.org/10.1007/s00259-023-06322-0